It is intriguing to speculate that similar mechanisms of IP preservation in HFSCs, identified in this study, are also active in various EGFR-dependent solid tumors and that EGFR inhibition renders them more immunogenic, thereby supporting anti-cancer therapy efficiency. Here, EGFR is linked to cancer.